Denileukin diftitox (DD; Ontak, Eisai, Woodcliff Lake, NJ) is an FDA-approved targeted therapy for cutaneous T-cell lymphoma (CTCL) [1]. This recombinant fusion protein (human interleukin 2 {IL-2} ...
No takes yet. Share an insight, caveat, or question.
Park et al. (2007) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: